At 9.7% CAGR, the North America dPCR and qPCR Market is Projected to be Worth US$ 7,429.03 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the North America dPCR and qPCR market was valued at US$ 3,551.08 million in 2022 and is expected to reach US$ 7,429.03 million by 2030, registering a CAGR of 9.7% from 2022 to 2030. Rising investments and funds for gene synthesis and increasing incidence of genetic and infectious diseases are among the critical factors attributed to the North America dPCR and qPCR market expansion.

Gene synthesis is the most accepted tool in the fields of recombinant DNA technology, which includes recombinant protein production and PCR technology for amplification as well as quantification purposes. In 2021, The synthetic biology startup Camena Bioscience, which supplies genes to the biotechnology and pharmaceutical sectors, completed a US$10 million Series A funding round headed by Mercia. With the additional funds, the company will expand operations and keep developing gSynth, its ground-breaking DNA synthesis platform. The technology platform and other related resources help the company to accelerate the development of gene synthesis. Companies have also increased their research and development funds for the enhancement of gene synthesis.

In 2020, EVONETIX LTD, a synthetic biology startup creating a desktop platform for high-fidelity, rapid, and scalable gene synthesis, announced the completion of its Series B financing round. The company, led by new investor Foresite Capital, raised US$ 30 million (£23 million) in this round. Investors such as Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, and Cambridge Consultants Ltd also participated in the round, Rising Tide Fund, and Civilization Ventures. Thus, rising investments made by government companies fuel the global gene synthesis market growth.

On the contrary, high costs of PCR systems hampers the growth of North America dPCR and qPCR market.

Based on treatment, the North America dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held 73.5% share of the North America dPCR and qPCR market in 2022, amassing US$ 2,611.41 million. It is projected to garner US$ 5,708.28 million by 2030 to expand at 10.3% CAGR during 2022–2030.

By product, the North America dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held 58.2% share of the North America dPCR and qPCR market in 2022, amassing US$ 2,067.70 million. It is projected to garner US$ 4,635.35 million by 2030 to expand at 10.6% CAGR during 2022–2030.

By application, the North America dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held 57.3% share of the North America dPCR and qPCR market in 2022, amassing US 2,033.10 million. It is projected to garner US$ 4,716.82 million by 2030 to expand at 11.1% CAGR during 2022–2030. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious diseases testing, and other applications.

By end user, the North America dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held 57.3% share of the North America dPCR and qPCR market in 2022, amassing US$ 2,033.10 million. It is projected to garner US$ 4,716.82 million by 2030 to expand at 11.1% CAGR during 2022–2030.

Based on country, the North America dPCR and qPCR market is segmented into segmented into US, Canada, and Mexico. The US held 83.8% share of North America dPCR and qPCR market in 2022, amassing US$ 2,975.20 million. It is projected to garner US$ 6,400.87 million by 2030 to expand at 10.1% CAGR during 2022–2030.

Key players operating in the North America dPCR and qPCR market are Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com